GAM Holding AG Reduces Stake in Haleon PLC Sponsored ADR (NYSE:HLN)

GAM Holding AG decreased its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 15.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 666,312 shares of the company's stock after selling 125,790 shares during the quarter. GAM Holding AG's holdings in Haleon were worth $6,856,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Riverbridge Partners LLC grew its holdings in Haleon by 43.1% in the first quarter. Riverbridge Partners LLC now owns 21,991 shares of the company's stock worth $226,000 after purchasing an additional 6,628 shares during the period. Blue Trust Inc. boosted its position in shares of Haleon by 9.5% during the 1st quarter. Blue Trust Inc. now owns 55,003 shares of the company's stock worth $566,000 after purchasing an additional 4,758 shares in the last quarter. QRG Capital Management Inc. grew its stake in shares of Haleon by 38.5% in the 1st quarter. QRG Capital Management Inc. now owns 451,968 shares of the company's stock valued at $4,651,000 after buying an additional 125,612 shares during the period. Janney Montgomery Scott LLC raised its stake in Haleon by 4.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 889,394 shares of the company's stock worth $9,152,000 after buying an additional 38,831 shares during the period. Finally, Optas LLC boosted its holdings in Haleon by 17.9% in the first quarter. Optas LLC now owns 21,337 shares of the company's stock worth $220,000 after acquiring an additional 3,240 shares in the last quarter. Institutional investors own 6.67% of the company's stock.

Haleon Stock Performance

Shares of Haleon stock traded up $0.01 during mid-day trading on Tuesday, hitting $10.50. 14,925,274 shares of the stock were exchanged, compared to its average volume of 9,158,512. Haleon PLC Sponsored ADR has a 12 month low of $8.25 and a 12 month high of $11.42. The company has a 50-day simple moving average of $10.70 and a 200 day simple moving average of $10.11. The company has a market capitalization of $47.19 billion, a P/E ratio of 26.91, a P/E/G ratio of 2.96 and a beta of 0.31. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.78 and a current ratio of 0.98.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on HLN shares. BNP Paribas Exane upgraded Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective for the company in a report on Tuesday, May 27th. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target for the company in a research note on Friday, May 9th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. Barclays reissued an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Finally, Hsbc Global Res downgraded Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Five analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.